Data and Specimen Access Stats

Scientific Updates Get updates: Email RSS

PPMI iPSC Lines — A Valuable Tool for Researchers

Mar 23, 2017

The Parkinson?s Progression Markers Initiative (PPMI) has expanded to include the generation of induced pluripotent stem cell (iPSC) lines from reprogrammed peripheral mononuclear blood cells (PBMCs) collected from PPMI participants. Study leadership hopes to complete 135 blood collections by the end of 2017; to date, over 50 PPMI participants have given blood samples. Cells lines […]

Continue reading...

Live Webinar February 24: 2016 PPMI Data Challenge Winners

Feb 9, 2017

In June of 2016, The Michael J. Fox Foundation challenged data scientists and computational analysts to work with PPMI?s unprecedented collection of open-access clinical, molecular, and imaging data to answer two fundamental questions about Parkinson?s disease: what are the subtypes of the disease, and what baseline factors predict disease progression? In total, forty researchers submitted […]

Continue reading...

The Michael J. Fox Foundation Announces $25,000 PPMI Data Challenge to Advance Parkinson?s Understanding and Study Design

Jun 8, 2016

Today The Michael J. Fox Foundation (MJFF) announced a challenge asking data scientists and computational analysts to work with researchers to answer fundamental questions about Parkinson?s that limit our understanding and slow drug testing. The PPMI Data Challenge offers $25,000 each to two teams that develop models to answer either: ? What factors at baseline predict […]

Continue reading...

2016 PPMI Annual Meeting held in New York City

May 20, 2016

The 2016 PPMI annual meeting took place on May 4-5 in New York City.  The meeting brought together 175 PPMI stakeholders from around the world, including PPMI leadership, site principal investigators, site coordinators and industry partners.  During the two day meeting, there was discussion of the data coming out of PPMI to date, plans for the […]

Continue reading...

PPMI Q1 2016 Study Update call

Mar 31, 2016

On March 11, Dr. Mark Frasier, Senior Vice President at the Michael J. Fox Foundation, shared an update on the PPMI study. Dr. Frasier summarized some of the key accomplishments of PPMI to date.

Continue reading...

Researchers identify biomarker for early cognitive decline in Parkinson’s disease patients using PPMI data

Feb 25, 2016

Many patients with Parkinson?s Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing new cognitive-enhancing treatments. New research using PPMI data published in the Journal of Parkinson?s Disease indicates that lower concentrations of ?-synuclein in cerebrospinal fluid (CSF) is associated with reduced performance on several cognitive tests.

Continue reading...

Dr. Omar El-Agnaf to use PPMI biospecimens for validation of cerebral spinal fluid ?-synuclein species as surrogate biomarkers for Parkinson?s disease

Feb 15, 2016

We are excited to announce another recent approval by our Biospecimen Review Committee. Dr. Omar El-Agnaf, Professor at Hamad Bin Khalifa University in Doha, Qatar, will be using PPMI biospecimens for a project entitled: Validation of CSF ?-synuclein species as surrogate biomarkers for Parkinson?s disease. Dr. El-Agnaf has recently reported higher levels of the oligomeric […]

Continue reading...

Dr. Martin Rabey to use PPMI biospecimens for validation of a blood based gene expression assay

Feb 1, 2016

A critical component of PPMI is the standardized, longitudinal collection of biospecimens. Each month the Biospecimen Review Committee examines requests for biospecimens collected through the PPMI study. We are excited to announce approval for Dr. Martin Rabey, the Chief Medical Officer of BioShai Ltd, for a project entitled: Validation of a blood based gene expression […]

Continue reading...

Update to PPMI Protocol

Jan 8, 2016

PPMI?s updated study protocol (version 11.0) allows for subjects enrolled in the Parkinson?s Disease (PD) and Healthy Control cohorts to continue participation in PPMI beyond month 60.  Subjects in these two cohorts consenting to amendment 10 will be followed through month 96 (V15). Subjects in the PD cohort will continue with annual in person visits […]

Continue reading...

Diffusion Tensor Imaging Reflects Degree of Motor Symptoms

Jul 13, 2015

In a recent publication in Movement Disorders, Zhang, et al. used PPMI data and found that diffusion tensor imaging (DTI) detected neural fiber abnormalities in people with Parkinson's disease (PD) and that the degree of deviation from normal neural fiber integrity is associated with the severity of motor symptoms in patients.

Continue reading...